Patents by Inventor Toon Laeremans
Toon Laeremans has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240103013Abstract: The present invention relates to the field of GPCR structure biology and signaling. In particular, the present invention relates to protein binding domains directed against or capable of specifically binding to a functional conformational state of a G-protein-coupled receptor (GPCR). More specifically, the present invention provides protein binding domains that are capable of increasing the stability of a functional conformational state of a GPCR, in particular, increasing the stability of a GPCR in its active conformational state. The protein binding domains of the present invention can be used as a tool for the structural and functional characterization of G-protein-coupled receptors bound to various natural and synthetic ligands, as well as for screening and drug discovery efforts targeting GPCRs. Moreover, the invention also encompasses the diagnostic, prognostic and therapeutic usefulness of these protein binding domains for GPCR-related diseases.Type: ApplicationFiled: July 26, 2023Publication date: March 28, 2024Inventors: Jan Steyaert, Els Pardon, Soren G.F. Rasmussen, Juan Jose Fung, Brian Kobilka, Toon Laeremans
-
Publication number: 20240026013Abstract: The present invention relates to CX3CR1-binding polypeptides, in particular polypeptides comprising specific immunoglobulin domains. The invention also relates to nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions comprising such polypeptides; and to uses of such polypeptides or such compositions, in particular for prophylactic, therapeutic and diagnostic purposes.Type: ApplicationFiled: June 9, 2022Publication date: January 25, 2024Applicant: Ablynx N.V.Inventors: Sanjaya Singh, Alisa K. Waterman, Erik Depla, Toon Laeremans, Diane Van Hoorick, Cedric Jozef Néotère Ververken
-
Publication number: 20230071321Abstract: The disclosure relates cells or cellular systems that express both a membrane protein and a binding domain directed to the membrane protein. Also, methods are provided that use such cells or cellular systems to produce higher amounts of the membrane proteins. Further, the cells or cellular systems can be used as tools for the structural and functional characterization of membrane proteins, as well as for screening and drug discovery efforts targeting membrane proteins.Type: ApplicationFiled: October 24, 2022Publication date: March 9, 2023Inventors: Jan Steyaert, Nico L.M. Callewaert, Toon Laeremans, Els Pardon, Kristof Vandewalle, Katrien Claes
-
Publication number: 20230046772Abstract: The present invention relates to CX3CR1-binding polypeptides, in particular polypeptides comprising specific immunoglobulin domains. The invention also relates to nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions comprising such polypeptides; and to uses of such polypeptides or such compositions, in particular for prophylactic, therapeutic and diagnostic purposes.Type: ApplicationFiled: June 9, 2022Publication date: February 16, 2023Applicant: Ablynx N.V.Inventors: Sanjaya Singh, Alisa K. Waterman, Erik Depla, Toon Laeremans, Diane Van Hoorick, Cedric Jozef Néotère Ververken
-
Patent number: 11479791Abstract: The disclosure relates cells or cellular systems that express both a membrane protein and a binding domain directed to the membrane protein. Also, methods are provided that use such cells or cellular systems to produce higher amounts of the membrane proteins. Further, the cells or cellular systems can be used as tools for the structural and functional characterization of membrane proteins, as well as for screening and drug discovery efforts targeting membrane proteins.Type: GrantFiled: February 12, 2018Date of Patent: October 25, 2022Inventors: Jan Steyaert, Nico L. M. Callewaert, Toon Laeremans, Els Pardon, Kristof Vandewalle, Katrien Claes
-
Publication number: 20220289837Abstract: The present invention relates to binding agents specific for the cystic fibrosis transmembrane conductance regulator (CFTR), which increase its thermal stability to provide for potent therapeutics. More particular, the immunoglobulin single variable domains (ISVDs) identified herein reveal novel binding sites on the nucleotide-binding domain 1 of CFTR, which allow to rescue pathogenic mutant F508del CFTR from proteasomal degradation. The binding agents are therefore considered suitable in treatment of cystic fibrosis. Finally, also crystalline structures demonstrating binding interfaces, and computer-assisted methods for selecting molecules able to stabilize CFTR are described.Type: ApplicationFiled: April 30, 2020Publication date: September 15, 2022Inventors: Jan Steyaert, Els Pardon, Toon Laeremans, Cedric Govaerts, Magdalena Grodecka, Maud Sigoillot, Marie Overtus, Marianne Sylvia Carlon, Marjolein Ensinck, Abel Garcia-Pino
-
Patent number: 11384151Abstract: The present invention relates to CX3CR1-binding polypeptides, in particular polypeptides comprising specific immunoglobulin domains. The invention also relates to nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions comprising such polypeptides; and to uses of such polypeptides or such compositions, in particular for prophylactic, therapeutic and diagnostic purposes.Type: GrantFiled: July 9, 2019Date of Patent: July 12, 2022Assignee: Ablynx N.V.Inventors: Sanjaya Singh, Alisa K. Waterman, Erik Depla, Toon Laeremans, Diane Van Hoorick, Cedric Jozef Neotere Ververken
-
Patent number: 11352422Abstract: Agents that specifically bind to an opioid receptor in a conformationally specific way can be used to induce a conformational change in the receptor. Such agents have therapeutic applications and can be used in X-ray crystallography studies of the receptor. Such agents can also be used to improve drug discovery via compound screening and/or structure-based drug design.Type: GrantFiled: March 15, 2019Date of Patent: June 7, 2022Assignees: VIB VZW, Vrije Univeriteit Brussel, Board of Trustees Leland Stanford Jr UniversityInventors: Jan Steyaert, Toon Laeremans, Els Pardon, Brian Kobilka, Aashish Manglik
-
Publication number: 20220099683Abstract: The present invention relates to the field of GPCR structure biology and signaling. In particular, the present invention relates to protein binding domains directed against or capable of specifically binding to a functional conformational state of a G-protein-coupled receptor (GPCR). More specifically, the present invention provides protein binding domains that are capable of increasing the stability of a functional conformational state of a GPCR, in particular, increasing the stability of a GPCR in its active conformational state. The protein binding domains of the present invention can be used as a tool for the structural and functional characterization of G-protein-coupled receptors bound to various natural and synthetic ligands, as well as for screening and drug discovery efforts targeting GPCRs. Moreover, the invention also encompasses the diagnostic, prognostic and therapeutic usefulness of these protein binding domains for GPCR-related diseases.Type: ApplicationFiled: October 21, 2021Publication date: March 31, 2022Inventors: Jan Steyaert, Els Pardon, Soren G.F. Rasmussen, Juan Jose Fung, Brian Kobilka, Toon Laeremans
-
Patent number: 11162954Abstract: The present invention relates to the field of GPCR structure biology and signaling. In particular, the present invention relates to protein binding domains directed against or capable of specifically binding to a functional conformational state of a G-protein-coupled receptor (GPCR). More specifically, the present invention provides protein binding domains that are capable of increasing the stability of a functional conformational state of a GPCR, in particular, increasing the stability of a GPCR in its active conformational state. The protein binding domains of the present invention can be used as a tool for the structural and functional characterization of G-protein-coupled receptors bound to various natural and synthetic ligands, as well as for screening and drug discovery efforts targeting GPCRs. Moreover, the invention also encompasses the diagnostic, prognostic and therapeutic usefulness of these protein binding domains for GPCR-related diseases.Type: GrantFiled: July 30, 2019Date of Patent: November 2, 2021Assignees: VIB VZW, Vrije Universiteit Brussel, Board of Trustees Leland Stanford Jr UniversityInventors: Jan Steyaert, Els Pardon, Soren G. F. Rasmussen, Juan Jose Fung, Brian Kobilka, Toon Laeremans
-
Patent number: 11162953Abstract: The present invention relates to the field of GPCR structure biology and signaling. In particular, the present invention relates to protein binding domains directed against or capable of specifically binding to a functional conformational state of a G-protein-coupled receptor (GPCR). More specifically, the present invention provides protein binding domains that are capable of increasing the stability of a functional conformational state of a GPCR, in particular, increasing the stability of a GPCR in its active conformational state. The protein binding domains of the present invention can be used as a tool for the structural and functional characterization of G-protein-coupled receptors bound to various natural and synthetic ligands, as well as for screening and drug discovery efforts targeting GPCRs. Moreover, the invention also encompasses the diagnostic, prognostic and therapeutic usefulness of these protein binding domains for GPCR-related diseases.Type: GrantFiled: July 30, 2019Date of Patent: November 2, 2021Assignees: VIB VZW, Vrije Universiteit Brussel, Board of Trustees of Leland Stanford Jr UniversityInventors: Jan Steyaert, Els Pardon, Soren G. F. Rasmussen, Juan Jose Fung, Brian Kobilka, Toon Laeremans
-
Publication number: 20200239534Abstract: The present disclosure relates to the field of G protein coupled receptor (GPCR) structural biology and signaling. In particular, the present disclosure relates to binding domains directed against and/or specifically binding to GPCR:G protein complexes. Also provided are nucleic acid sequences encoding such binding domains and cells expressing or capable of expressing such binding domains. The binding domains of the present disclosure can be used as universal tools for the structural and functional characterization of G-protein coupled receptors in complex with downstream heterotrimeric G proteins and bound to various natural or synthetic ligands, for investigating the dynamic features of G protein activation, as well as for screening and drug discovery efforts that make use of GPCR:G protein complexes.Type: ApplicationFiled: April 17, 2020Publication date: July 30, 2020Inventors: Jan Steyaert, Els Pardon, Toon Laeremans, Brian Kobilka, Soren G.F. Rasmussen, Sebastien Granier, Roger K. Sunahara
-
Patent number: 10626154Abstract: The present disclosure relates to the field of G protein coupled receptor (GPCR) structural biology and signaling. In particular, the present disclosure relates to binding domains directed against and/or specifically binding to GPCR:G protein complexes. Also provided are nucleic acid sequences encoding such binding domains and cells expressing or capable of expressing such binding domains. The binding domains of the present disclosure can be used as universal tools for the structural and functional characterization of G-protein coupled receptors in complex with downstream heterotrimeric G proteins and bound to various natural or synthetic ligands, for investigating the dynamic features of G protein activation, as well as for screening and drug discovery efforts that make use of GPCR:G protein complexes.Type: GrantFiled: May 1, 2017Date of Patent: April 21, 2020Assignees: VIB VZW, Vrije Universiteit Brussel, The Board of Trustees of the Leland Stanford Junior University, The Regents of the University of MichiganInventors: Jan Steyaert, Els Pardon, Toon Laeremans, Brian Kobilka, Soren G. F. Rasmussen, Sebastien Granier, Roger K. Sunahara
-
Patent number: 10544216Abstract: The present invention relates to biological materials against P2X7 and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the biological materials of the present invention inhibit the biological activity of the P2X7 receptor, such as activation by ATP.Type: GrantFiled: January 19, 2018Date of Patent: January 28, 2020Assignees: Ablynx N.V., University Medical Center Hamburg-EppendorfInventors: Welbeck Owusu Danquah, Friedrich Nolte, Catelijne Stortelers, Toon Laeremans
-
Publication number: 20200025773Abstract: The present invention relates to the field of GPCR structure biology and signaling. In particular, the present invention relates to protein binding domains directed against or capable of specifically binding to a functional conformational state of a G-protein-coupled receptor (GPCR). More specifically, the present invention provides protein binding domains that are capable of increasing the stability of a functional conformational state of a GPCR, in particular, increasing the stability of a GPCR in its active conformational state. The protein binding domains of the present invention can be used as a tool for the structural and functional characterization of G-protein-coupled receptors bound to various natural and synthetic ligands, as well as for screening and drug discovery efforts targeting GPCRs. Moreover, the invention also encompasses the diagnostic, prognostic and therapeutic usefulness of these protein binding domains for GPCR-related diseases.Type: ApplicationFiled: July 30, 2019Publication date: January 23, 2020Inventors: Jan Steyaert, Els Pardon, Soren G.F. Rasmussen, Juan Jose Fung, Brian Kobilka, Toon Laeremans
-
Publication number: 20190383827Abstract: The present invention relates to the field of GPCR structure biology and signaling. In particular, the present invention relates to protein binding domains directed against or capable of specifically binding to a functional conformational state of a G-protein-coupled receptor (GPCR). More specifically, the present invention provides protein binding domains that are capable of increasing the stability of a functional conformational state of a GPCR, in particular, increasing the stability of a GPCR in its active conformational state. The protein binding domains of the present invention can be used as a tool for the structural and functional characterization of G-protein-coupled receptors bound to various natural and synthetic ligands, as well as for screening and drug discovery efforts targeting GPCRs. Moreover, the invention also encompasses the diagnostic, prognostic and therapeutic usefulness of these protein binding domains for GPCR-related diseases.Type: ApplicationFiled: July 30, 2019Publication date: December 19, 2019Inventors: Jan Steyaert, Els Pardon, Soren G.F. Rasmussen, Juan Jose Fung, Brian Kobilka, Toon Laeremans
-
Publication number: 20190383826Abstract: The present invention relates to the field of GPCR structure biology and signaling. In particular, the present invention relates to protein binding domains directed against or capable of specifically binding to a functional conformational state of a G-protein-coupled receptor (GPCR). More specifically, the present invention provides protein binding domains that are capable of increasing the stability of a functional conformational state of a GPCR, in particular, increasing the stability of a GPCR in its active conformational state. The protein binding domains of the present invention can be used as a tool for the structural and functional characterization of G-protein-coupled receptors bound to various natural and synthetic ligands, as well as for screening and drug discovery efforts targeting GPCRs. Moreover, the invention also encompasses the diagnostic, prognostic and therapeutic usefulness of these protein binding domains for GPCR-related diseases.Type: ApplicationFiled: July 1, 2019Publication date: December 19, 2019Inventors: Jan Steyaert, Els Pardon, Soren G.F. Rasmussen, Juan Jose Fung, Brian Kobilka, Toon Laeremans
-
Publication number: 20190383829Abstract: The present invention relates to the field of GPCR structure biology and signaling. In particular, the present invention relates to protein binding domains directed against or capable of specifically binding to a functional conformational state of a G-protein-coupled receptor (GPCR). More specifically, the present invention provides protein binding domains that are capable of increasing the stability of a functional conformational state of a GPCR, in particular, increasing the stability of a GPCR in its active conformational state. The protein binding domains of the present invention can be used as a tool for the structural and functional characterization of G-protein-coupled receptors bound to various natural and synthetic ligands, as well as for screening and drug discovery efforts targeting GPCRs. Moreover, the invention also encompasses the diagnostic, prognostic and therapeutic usefulness of these protein binding domains for GPCR-related diseases.Type: ApplicationFiled: July 30, 2019Publication date: December 19, 2019Inventors: Jan Steyaert, Els Pardon, Soren G.F. Rasmussen, Juan Jose Fung, Brian Kobilka, Toon Laeremans
-
Publication number: 20190383825Abstract: The present invention relates to the field of GPCR structure biology and signaling. In particular, the present invention relates to protein binding domains directed against or capable of specifically binding to a functional conformational state of a G-protein-coupled receptor (GPCR). More specifically, the present invention provides protein binding domains that are capable of increasing the stability of a functional conformational state of a GPCR, in particular, increasing the stability of a GPCR in its active conformational state. The protein binding domains of the present invention can be used as a tool for the structural and functional characterization of G-protein-coupled receptors bound to various natural and synthetic ligands, as well as for screening and drug discovery efforts targeting GPCRs. Moreover, the invention also encompasses the diagnostic, prognostic and therapeutic usefulness of these protein binding domains for GPCR-related diseases.Type: ApplicationFiled: June 28, 2019Publication date: December 19, 2019Inventors: Jan Steyaert, Els Pardon, Soren G.F. Rasmussen, Juan Jose Fung, Brian Kobilka, Toon Laeremans
-
Publication number: 20190383828Abstract: The present invention relates to the field of GPCR structure biology and signaling. In particular, the present invention relates to protein binding domains directed against or capable of specifically binding to a functional conformational state of a G-protein-coupled receptor (GPCR). More specifically, the present invention provides protein binding domains that are capable of increasing the stability of a functional conformational state of a GPCR, in particular, increasing the stability of a GPCR in its active conformational state. The protein binding domains of the present invention can be used as a tool for the structural and functional characterization of G-protein-coupled receptors bound to various natural and synthetic ligands, as well as for screening and drug discovery efforts targeting GPCRs. Moreover, the invention also encompasses the diagnostic, prognostic and therapeutic usefulness of these protein binding domains for GPCR-related diseases.Type: ApplicationFiled: July 30, 2019Publication date: December 19, 2019Inventors: Jan Steyaert, Els Pardon, Soren G.F. Rasmussen, Juan Jose Fung, Brian Kobilka, Toon Laeremans